ATW SPAC Management’s Estrella Immunopharma ESLA Stock Holding History

ATW SPAC Management’s Portfolio ESLA Stock Details ESLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$46K	Hold	40,000	–	–	0.06%	83
2025 Q2	$38.4K	Hold	40,000	–	–	0.06%	63
2025 Q1	$37.1K	Hold	40,000	–	–	0.06%	55
2024 Q4	$48K	Hold	40,000	–	–	0.07%	50
2024 Q3	$46.4K	Hold	40,000	–	–	0.05%	67
2024 Q2	$42K	Hold	40,000	–	–	0.05%	72
2024 Q1	$49.6K	Hold	40,000	–	–	0.06%	63
2023 Q4	$44.4K	Buy	+40,000	New	+$60.5K	0.06%	64
2022 Q4	–	Sell	-390,000	Closed	-$3.92M	–	209
2022 Q3	$3.92M	Hold	390,000	–	–	0.63%	69
2022 Q2	$3.9M	Hold	390,000	–	–	0.56%	72
2022 Q1	$3.9K	Hold	390,000	–	–	0.53%	72
2021 Q4	$3.87M	Hold	390,000	–	–	0.59%	64
2021 Q3	$3.86M	Buy	+390,000	New	+$3.84M	0.72%	51

Other funds holding ESLA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MCP

Maso Capital Partners Hong Kong $60.9M AUM 0.32% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

ATW SPAC Management's ESLA Position: Q3 2025 in Review

ATW SPAC Management held its Estrella Immunopharma (ESLA) position steady in Q3 2025 at 40,000 shares worth $46K. The position accounts for 0.06% of the portfolio, ranked #83.

ATW SPAC Management first reported a position in ESLA in Q3 2021 and has held it in 13 quarters since. The position peaked at $3.92M in Q3 2022. 13 funds tracked by Wall St. Rank hold ESLA as of Q3 2025.

ATW SPAC Management held 40,000 shares of Estrella Immunopharma worth $46K as of Q3 2025.
ATW SPAC Management left its Estrella Immunopharma share count unchanged in Q3 2025.
Estrella Immunopharma made up 0.06% of ATW SPAC Management's portfolio in Q3 2025, its #83 holding.
ATW SPAC Management first reported a position in Estrella Immunopharma in Q3 2021 and has held it in 13 quarters since.
ATW SPAC Management's Estrella Immunopharma position peaked at $3.92M in Q3 2022.
13 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q3 2025.

Based on ATW SPAC Management's 13F filing for Q3 2025, filed 12 Nov 2025.